| 46.91 -0.28 (-0.59%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 58.86 | 1-year : | 68.75 |
| Resists | First : | 50.39 | Second : | 58.86 |
| Pivot price | 39.83  |
|||
| Supports | First : | 37.17 | Second : | 29 |
| MAs | MA(5) : | 45.22 |
MA(20) : | 38.39 |
| MA(100) : | 25.54 |
MA(250) : | 25.46  |
|
| MACD | MACD : | 3.3 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 81.5 |
D(3) : | 81.4 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 130 | Low : | 6.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNXP ] has closed below upper band by 10.0%. Bollinger Bands are 36.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.83 - 49.08 | 49.08 - 49.23 |
| Low: | 44.94 - 45.25 | 45.25 - 45.45 |
| Close: | 46.45 - 46.93 | 46.93 - 47.24 |
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Thu, 10 Jul 2025
Tonix Pharma stock up after data for pain drug (TNXP:NASDAQ) - Seeking Alpha
Mon, 30 Jun 2025
Tonix Pharmaceuticals Joins Elite Russell Indexes Ahead of Major FDA Decision - Stock Titan
Mon, 30 Jun 2025
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Yahoo Finance
Mon, 16 Jun 2025
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Fri, 13 Jun 2025
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion? (NASDAQ:TNXP) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 908 (K) |
| EPS | 356.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.22 |
| Profit Margin | 0 % |
| Operating Margin | -661 % |
| Return on Assets (ttm) | -27.6 % |
| Return on Equity (ttm) | -91.5 % |
| Qtrly Rev. Growth | -2.1 % |
| Gross Profit (p.s.) | 0.4 |
| Sales Per Share | 1.36 |
| EBITDA (p.s.) | -9.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | 0.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.78 |
| Price to Sales | 34.38 |
| Price to Cash Flow | -5.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|